The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma

Abstract

Purpose: To investigate the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease inhibitors (PI) to HIV-positive patients affected by Kaposi's sarcoma (KS). Patients and methods: A group of 18 patients with extensive or rapidly progressing AIDS-related KS received DaunoXome at… (More)
DOI: 10.1007/s002800051025

Topics

4 Figures and Tables

Cite this paper

@article{Fumagalli2000ThePO, title={The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma}, author={Luca Fumagalli and Massimo Zucchetti and Idria Parisi and Maria Grazia Vigan{\`o} and Bruno Zecca and Anna Maria Laura Careddu and Maurizio D'Incalci and Adriano Lazzarin}, journal={Cancer Chemotherapy and Pharmacology}, year={2000}, volume={45}, pages={495-501} }